KRAS and cholangiocarcinoma: Taken together, these data provide evidence toward a striking molecular similarity between metastatic cholangiocarcinoma and KRAS wildtype mPDAC that is not shared with KRAS mutant mPDAC, while being observed in two orthogonal study cohorts of patient tumor samples.